Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Can Sanofi parlay low Lantus prices into Toujeo sales? That's the billion-dollar question

It was Sanofi's first public event without ex-CEO Chris Viehbacher. But the French drugmaker's investor day didn't bring much in the way of surprise. As expected, Sanofi Chairman Serge Weinberg talked up the launches expected for next year and beyond, all $38 billion worth.

France strikes big hep C treatment deal for Gilead's Sovaldi

France threatened to tax hepatitis C drugmakers if they insisted on charging nosebleed prices. Apparently, the arm-twisting worked: The French government says it has cut a deal with Gilead Sciences to get Sovaldi at the lowest price in Europe.

So long, patent cliff. Hello, hep C and cancer. Welcome to $1.3T in global drug spending

What happens when the worst of the pharma patent cliff passes and new drug approvals surge? A big leap in drug spending. After a sluggish 5 years or so, global outlay on pharma products will jump by up to 30%--or $335 billion--by 2018, according to a new report from the IMS Institute of Healthcare Informatics.

Novartis seeks tech partners for brave new beyond-the-pill world

Novartis hasn't been shy about digital. The Swiss drugmaker has rolled out app after app to help patients track their symptoms and stay on their drugs. But CEO Joe Jimenez says the company is about to do a lot more than that.

Warning to Takeda, Bayer, Novartis and AstraZeneca: CEO-hunting Sanofi may poach your executives

Those fast-and-furious rumors about Chris Viehbacher's impending ouster at Sanofi? The new round of chatter about Viehbacher's replacement is almost as intense. Bloomberg has a list of healthcare execs said to be up for the job, and they span a who's who of Big Pharma companies.

AstraZeneca's anti-Pfizer growth promises? At least one big investor is buying

When Pfizer and Merck KGaA announced their big immuno-oncology deal Monday, market watchers immediately started extrapolating. The tie-up means Pfizer won't come back for another try at AstraZeneca, some say. But others figure that there's still a solid chance of Pfizer, round two.

Valeant and Allergan's wining-and-dining shows pharma's faith in doctor influence

Payers may be grabbing the spotlight as script gatekeepers, but if the recently concluded takeover fight between Valeant and Allergan is any indication, doctors are still extremely influential--and companies still believe they can be influenced.

Generics makers, execs face potential criminal charges in U.S. pricing probe

After months of percolating discontent about generic drug price hikes, the U.S. Senate is hauling drugmakers to a hearing this week. But the real threat lies at the Department of Justice, which is likely considering criminal prosecution for price-fixing and other antitrust violations, Law.com reports.

Surprise: Merck's cholesterol combo Vytorin hits goal in long-awaited outcomes trial

Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.

Pfizer, Gates Foundation team up on low-cost injectable contraceptive

Pfizer inked a deal with the Bill & Melinda Gates Foundation to roll out a long-acting contraceptive in 69 of the world's poorest countries.